Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose-Escalating Study of ALIMTA and Cyclophosphamide Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer

NCT00190671 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00190671
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00190671 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose-Escalating Study of ALIMTA and Cyclophosphamide Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2005
Completion date
March 31, 2008
Enrollment
103 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer